Johnson & Johnson's Oncology Division Drives Growth Amid Dividend Stability
Johnson & Johnson (JNJ) has quietly positioned itself as a growth machine through its oncology division, particularly with the success of cancer drug Darzalex. The company reported global sales growth for Darzalex at nearly 19% in Q2 and is on track to achieve $50 billion annually from cancer drugs by 2030. Despite spinning off consumer brands into Kenvue last year, Johnson & Johnson remains a strong dividend payer with an impressive record of 64 consecutive years of per-share dividend increases. The company's focus shift toward prescription drugs and medical devices has led to consistent revenue growth in the high teens from its oncology business. The outlook for cancer treatment is robust, projected by Precedence Research to grow at a compound annual rate of 11.3% through 2035. Johnson & Johnson aims to maintain market leadership as it navigates patent expirations on other drugs like Stelara.
Tickers: $JNJ
Topics: Darzalex Johnson & Johnson oncology drugs pharmaceuticals